QNTM•Quantum BioPharma shareholders approved authority for a share consolidation of up to 10-for-1 and a name change at the November 10, 2026, meeting. They also approved an equity incentive plan and elected all five director nominees.
At its November 10, 2026, annual general and special meeting, Quantum BioPharma shareholders authorized a share consolidation of up to 10-for-1 and approved a name change, with the board authorized to choose the new name. Disinterested shareholders approved continued board authority to issue additional Class A Multiple Voting Shares to Permitted Holders; shareholders also adopted the omnibus equity incentive plan and elected all five director nominees. MNP LLP was reappointed auditor, with the audit committee authorized to set its remuneration.
